SecBot SecBot

CPIX

CUMBERLAND PHARMACEUTICALS INC
Nasdaq· Pharmaceutical Preparations· Inc. TN· CIK 0001087294 Biotech & Drug Discovery
$6.78 −1.71 (−20.14%)
Oct 26 4:00 PM ET · prev $8.49
Market cap
$127.1M
Micro cap
Next earnings
Nov 10
in 15 days
1 year
+112.5%
from $3.19 · Oct 27
30 days
−12.2%
from $7.72
52-week range
$1.90–8.97
−24% from high · low Nov 17
Avg volume 20D
48.4K
Oct 21 spike 142.0K
Short interest
348.9K
≈2.3% of shares · +38.2%
Days to cover
7.5
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 10, 2026
Strongest NEUTRAL Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 3 added (0 new), 0 trimmed or exited.

  • Short sellersBUILDING

    Short interest +38.2% to 348.9K shares. 7.5 days to cover, ≈2.3% of shares.

  • TrendRANGE

    8% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCDOUBLED73,391$475.6K
JANE STREET GROUP, LLCDOUBLED56,741$367.7K
UBS Group AGDOUBLED26,339$170.7K
UBS Group AGTRIM5,189$16.9K
TWO SIGMA INVESTMENTS, LPTRIM24,485$97.5K
UBS Group AGDOUBLED15,386$61.2K
NewEdge Advisors, LLCADD1,203$4.8K
BANK OF AMERICA CORP /DE/TRIM9$36.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Dec 2019
Recent actions
DateFirmActionRating
Dec 3, 2019B. Riley Securities
MAINTAIN
MAINTAINBuy
Nov 18, 2019B. Riley Securities
MAINTAIN
MAINTAINBuy
Aug 17, 2018B. Riley Securities
MAINTAIN
MAINTAINBuy
Apr 17, 2018B. Riley Securities
INITIATE
INITIATEBuy
Apr 10, 2013UBS
MAINTAIN
MAINTAINNeutral
Nov 12, 2012UBS
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Mar 18, 2026
Krogulski Kenneth
Director
AWARD$11.2K
Mar 18, 2026
Young Caroline
Director
AWARD$5.0K
Mar 18, 2026
Herman James L
VP and Chief Compliance Office
AWARD$7.0K
Mar 18, 2026
Galante Joseph C
Director
AWARD$5.0K
Mar 18, 2026
Jones James
Director
AWARD$5.0K
Mar 18, 2026
Krogulski Kenneth
Director
AWARD$5.0K
Mar 18, 2026
Bitterman Chris T.
Vice Pres Sales & Marketing
AWARD$8.4K
Mar 18, 2026
Anthony Todd M.
Vice Pres Organizational Dev
AWARD$8.4K

Earnings setup

Estimates
Nov 10
reports in 15 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
348,880
shares short
+38.2%
vs prior settlement
7.5
days to cover
≈2.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for…
8-K — Impact 4/10
Oct 23, 2026 Other
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 /PR
Aug 28, 2026 SEC
Cumberland Pharmaceuticals disclosed that long-term safety and efficacy data from the open-label extension of its…
8-K — Impact 5/10
Jul 13, 2026 Press
Cumberland Pharmaceuticals declared a special dividend of $1.50 per share and authorized a $5M buyback, returning…
Impact 7/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
73,391 shares ($475.6K)
Jun 30, 2026 Inst.
JANE STREET GROUP, LLC — DOUBLED
56,741 shares ($367.7K)
May 26, 2026 SEC
Cumberland Pharmaceuticals is seeking shareholder approval to sell its FDA-approved commercial product portfolio…
DEFM14A — Impact 7/10
Mar 18, 2026 Insider
Krogulski Kenneth was granted 4,000 shares
Director @ $2.80 ($11.2K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
CPIX Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Oct 23, 2026
Press release
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc…
Oct 23, 2026
Company news
CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL
NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company…
Aug 4, 2026
Earnings
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026…
Aug 4, 2026
Earnings date
CPIX Q2 2026 Earnings Scheduled — 2026-08-04
Aug 3, 2026
Earnings date
CPIX Q2 2026 Earnings Scheduled — 2026-08-03

SecBot reports

5 filings · 1 press release · 2 bullish · 1 bearish · 2 neutral
All CPIX filing & press-release reports (6)